News
03-16-2015, 10:40 AM
Vaxil Bio, a leading developer of immunotherapeutic products to treat cancer and infectious diseases, reports today that its lead drug candidate, ImMucin has received orphan drug designation from the European Medicines Agency of the European Commission for the treatment of Multiple Myeloma (MM), a blood cancer.
More... (http://www.news-medical.net/news/20150316/Vaxil-Bios-ImMucin-receives-EMA-orphan-drug-designation-for-treatment-of-Multiple-Myeloma.aspx)
More... (http://www.news-medical.net/news/20150316/Vaxil-Bios-ImMucin-receives-EMA-orphan-drug-designation-for-treatment-of-Multiple-Myeloma.aspx)